Header Complement Therapeutics

With a potentially highly differentiated lead asset combined with a precision medicine approach, we are excited by the opportunity to further develop CTx001 for the treatment of GA through to the clinic. The support of this broad syndicate enables us to generate additional data demonstrating CTx001’s unique and differentiated mechanism of action, with the potential to transform the treatment landscape in geographic atrophy.

Dr. Rafiq Hasan - CEO

Complement Therapeutics

Complement Therapeutics (CTx), a spin-out of the University of Manchester founded in 2021, aims to transform the treatment of complement-mediated conditions by developing novel therapies in ophthalmology and beyond.

Icon entry


Icon employees


Icon location

Germany & UK

When ambition meets ambition

The financing round will allow Complement Therapeutics to transform the treatment of complement-mediated conditions by developing novel therapies such as CTx001, an innovative AAV gene therapy for the treatment of geographic atrophy, a progressive and advanced form of age-related macular degeneration (AMD) associated with significant, irreversible loss of vision.

Furthermore, it will allow CTx to evaluate its pipeline assets for non-ocular indications as well as further develop the novel Complement Precision Medicine (CPM) platform.

Our investment in CTx is a key example that resembles the core of  our Life Sciences strategy i.e. to invest in companies where cutting-edge science could lead to a potential paradigm shift in the treatment and lives of patients.

Together, we build a leading company

A strong specialized investor base meets a very experienced and dedicated management team and together we are convinced that Complement Therapeutics will be able to make real difference to patients that have limited treatment options today.


Developing the next generation of complement medicines